Klinische, immunologische en functionele studie van ADA2-deficiëntie

ADA2 deficiency is a devastating rare inherited disorder caused by biallelic deleterious mutations in the ADA2 gene. Clinical manifestations include vasculopathy ranging from cutaneous vasculopathy (livedo) to lacunar brain infarction. Moreover, patients can have bone marrow failure and immunodeficiency. While anti-TNF agents are usually effective in controlling vasculopathy, bone marrow failure and immunodeficiency are often refractory. In part, ineffective treatment is lacking because the pathophysiology of ADA2 deficiency is incompletely understood. The goal of this ERC funded project is to investigate the role of ADA2 deficiency in ill explained forms of immunodeficiency and bone marrow failure as well as acute neurological manifestations. To this end, we will conduct clinical studies, immunophenotyping, proteomics and genomics, and in depth functional studies of the monocyte-endothelium interaction as well as endothelium and monocyte characteristics in ADA2 deficiency in comparison with patients without ADA2 deficiency and healthy controls.

Publication Details

Journal
Lirias (KU Leuven)
Published
2024-12-06
Primary Topic
Adenosine and Purinergic Signaling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Klinische, immunologische en functionele studie van ADA2-deficiëntie

Lirias (KU Leuven)
Adenosine and Purinergic Signaling
article

Klinische, immunologische en functionele studie van ADA2-deficiëntie

article en

Abstract

ADA2 deficiency is a devastating rare inherited disorder caused by biallelic deleterious mutations in the ADA2 gene. Clinical manifestations include vasculopathy ranging from cutaneous vasculopathy (livedo) to lacunar brain infarction. Moreover, patients can have bone marrow failure and immunodeficiency. While anti-TNF agents are usually effective in controlling vasculopathy, bone marrow failure and immunodeficiency are often refractory. In part, ineffective treatment is lacking because the pathophysiology of ADA2 deficiency is incompletely understood. The goal of this ERC funded project is to investigate the role of ADA2 deficiency in ill explained forms of immunodeficiency and bone marrow failure as well as acute neurological manifestations. To this end, we will conduct clinical studies, immunophenotyping, proteomics and genomics, and in depth functional studies of the monocyte-endothelium interaction as well as endothelium and monocyte characteristics in ADA2 deficiency in comparison with patients without ADA2 deficiency and healthy controls.

Lirias (KU Leuven)
Good health and well-being, Partnerships for the goals
Openalex Percentile: Top 45%
Adenosine and Purinergic Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.